Navigation Links
Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital
Date:10/29/2008

QUEBEC, Oct. 29 /PRNewswire/ -- The Fondation du Centre hospitalier universitaire de Sherbrooke (CHUS) is proud to announce that Waters Corporation has donated a Waters(R) Synapt(TM) MS System, the latest generation of mass spectrometers. This gift -- worth a total C$1.1 million -- is the result of a partnership between Waters and CHUS which is critical to the creation of the Centre d'expertise en spectrometrie de masse clinique Waters-CHUS (Waters-CHUS Expertise Center for Clinical Mass Spectrometry) for screening, clinical diagnosis, and assessment of treatments for specific hereditary diseases, as well as for patient surveillance and management.

CHUS formally acknowledged the donation made by Waters Corporation at a ceremony officially inaugurating the laboratory.

The acquisition of this state-of-the-art technology and establishment of the center will enable the CHUS to sustain its position at the cutting edge of genetics in detecting hereditary metabolic diseases and in research into assessing metabolites for various other diseases. The device is in addition to the acquisition of the first mass spectrometer -- a Waters Quattro(TM) micro - - made possible by the Fondation du CHUS in 2005. At that time, the CHUS had the distinction of being Quebec's first university hospital to put this technology to use in a clinical setting.

The Centre d'expertise en spectrometrie de masse clinique Waters-CHUS will come under the direction of biochemist Christiane Auray-Blais, PhD, researcher with the mother-child thrust of the CHUS Centre de recherche clinique Etienne- Le Bel, and professor in the Faculty of Medicine and Health Sciences at the Universite de Sherbrooke.

"Patients will be the first to benefit from this unique partnership, since it will make new clinical tests available to the public. This mass spectrometer will enable us to identify previously unknown biomarkers, that is, characteristics that can be objectively measured biochemi
'/>"/>

SOURCE Sherbrooke Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Silver Lake Research Unveils Watersafe(R) Well Water Test Kit
2. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
3. David H. Murdock Research Institute Taps Waters for Laboratory Technology
4. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
5. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
9. BioElectronics Corporation Announces Singapore and Malaysia Sales
10. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
11. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... develops, manufactures, and markets specialty pharmaceutical products in ... completed Phase I clinical trials of its novel ... to be the most widely prescribed class of ...
... SAN DIEGO, Sept. 22 Marshall Edwards, Inc. (Nasdaq: ... development of novel anti-cancer therapeutics, announced today that Daniel P. ... update on Marshall Edwards and its novel oncology programs at ... beginning at 4:30 p.m. EDT from the New York Palace ...
... Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
...
... A-type ribonucleases Product Description: ,QIAGEN RNase Inhibitor ... binds noncovalently and inactivates a variety of ... It does not interfere with RNase T1, ... RNase Inhibitor inhibits greater than 90% of ...
...
Biology Products: